Slingshot members are tracking this event:

Celgene (CELG) Phase III data readout of AUGMENT trial testing Revlimid in treating relapsed and/or refractory Follicular lymphoma expected by end of 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
CELG Community voting in process

Additional Information

Additional Relevant Details page
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 23, 2018
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Revlimid, Augment, Indolent Non-hodgkin Lymphoma, Phase 3 Study